Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6AHO2
|
|||
| Drug Name |
LY3410738
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxalosuccinate decarboxylase (IDH1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Warburg Effect | |||
| WikiPathways | TCA Cycle and PDHc | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Peroxisomal lipid metabolism | ||||
| Glutathione metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04521686) Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations. U.S. National Institutes of Health. | |||
| REF 2 | LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML). Cancer Res 2020;80(16 Suppl):Abstract nr 6417. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.